Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00OVC
|
|||
| Former ID |
DIB016808
|
|||
| Drug Name |
EVT-201
|
|||
| Synonyms |
IDDBCP221837
Click to Show/Hide
|
|||
| Indication | Insomnia [ICD-11: 7A00-7A0Z] | Phase 2 | [1] | |
| Company |
Roche Holding AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H17ClN6O2
|
|||
| Canonical SMILES |
CN1CC2=C(N=CN2C3=C(C1=O)C(=CC=C3)Cl)C4=NOC(=N4)CN(C)C
|
|||
| InChI |
1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
|
|||
| InChIKey |
JCYLWUVDHLVGER-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 308239-86-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Modulator | [2] |
| GABA(A) receptor gamma-3 (GABRG3) | Target Info | Modulator | [3] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00380003) Efficacy Study of EVT 201 to Treat Insomnia. U.S. National Institutes of Health. | |||
| REF 2 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.